CU20230031A7 - Método para la detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia - Google Patents

Método para la detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia

Info

Publication number
CU20230031A7
CU20230031A7 CU2023000031A CU20230031A CU20230031A7 CU 20230031 A7 CU20230031 A7 CU 20230031A7 CU 2023000031 A CU2023000031 A CU 2023000031A CU 20230031 A CU20230031 A CU 20230031A CU 20230031 A7 CU20230031 A7 CU 20230031A7
Authority
CU
Cuba
Prior art keywords
factor
antibody
fxi
xia
detection
Prior art date
Application number
CU2023000031A
Other languages
English (en)
Inventor
Daniel M Bloomfield
Debra A Freedholm
Jonathan E Freeman
Royston J Glasspool
Yasser Khder
Original Assignee
Anthos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthos Therapeutics Inc filed Critical Anthos Therapeutics Inc
Publication of CU20230031A7 publication Critical patent/CU20230031A7/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96452—Factor XI (3.4.21.27)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

<p>La presente divulgación se refiere a un método para detectar un anticuerpo antifármaco (ADA) contra un anticuerpo anti-Factor XI (FXI) o anti-Factor XIa (FXIa) o un fragmento de unión a antígeno de este, caracterizado porque el método comprende:</p> <p>a. incubar una muestra con un ácido para disociar los complejos de antígeno y anticuerpo anti-FXI o anti-FXIa o disociar complejos del ADA y del anticuerpo anti-FXI o anti-Factor XIa presentes en la muestra para formar una solución de digestión ácida,</p> <p>b. incubar la solución de igestión ácida en una placa recubierta con el anticuerpo anti-FXI o anti- XIa o un fragmento de unión a antígeno de este,</p> <p>c. neutralizar la solución de digestión ácida y</p> <p>d. detectar la presencia de los ADA mediante el uso de un cóctel de detectores rutenilados.</p> <p> </p> <p> </p>
CU2023000031A 2020-12-18 2021-12-17 Método para la detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia CU20230031A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127536P 2020-12-18 2020-12-18
PCT/US2021/064117 WO2022133263A1 (en) 2020-12-18 2021-12-17 Methods for the detection of anti-drug antibodies against factor xi and/or factor xia antibodies

Publications (1)

Publication Number Publication Date
CU20230031A7 true CU20230031A7 (es) 2024-02-07

Family

ID=82059801

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2023000031A CU20230031A7 (es) 2020-12-18 2021-12-17 Método para la detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia

Country Status (18)

Country Link
US (1) US20240077497A1 (es)
EP (1) EP4264278A1 (es)
JP (1) JP2023554347A (es)
KR (1) KR20230121120A (es)
CN (1) CN116601491A (es)
AR (1) AR124434A1 (es)
AU (1) AU2021401421A1 (es)
CA (1) CA3199482A1 (es)
CL (1) CL2023001709A1 (es)
CO (1) CO2023008150A2 (es)
CR (1) CR20230313A (es)
CU (1) CU20230031A7 (es)
EC (1) ECSP23053645A (es)
IL (1) IL302904A (es)
MX (1) MX2023007281A (es)
PE (1) PE20231679A1 (es)
TW (1) TW202242414A (es)
WO (1) WO2022133263A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240027432A1 (en) * 2022-07-13 2024-01-25 Regeneron Pharmaceuticals, Inc. Mild acid immunoassays for detection of analytes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
JP7161534B2 (ja) * 2017-11-29 2022-10-26 エフ．ホフマン－ラ ロシュ アーゲー 標的による干渉が抑制された抗薬物抗体アッセイ
CA3135004A1 (en) * 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays

Also Published As

Publication number Publication date
CN116601491A (zh) 2023-08-15
IL302904A (en) 2023-07-01
EP4264278A1 (en) 2023-10-25
AU2021401421A1 (en) 2023-06-22
WO2022133263A1 (en) 2022-06-23
KR20230121120A (ko) 2023-08-17
CL2023001709A1 (es) 2023-11-17
JP2023554347A (ja) 2023-12-27
AR124434A1 (es) 2023-03-29
CA3199482A1 (en) 2022-06-23
TW202242414A (zh) 2022-11-01
ECSP23053645A (es) 2023-08-31
PE20231679A1 (es) 2023-10-19
CR20230313A (es) 2023-08-18
CO2023008150A2 (es) 2023-06-30
US20240077497A1 (en) 2024-03-07
MX2023007281A (es) 2023-09-04

Similar Documents

Publication Publication Date Title
Schläfli et al. Reliable LC3 and p62 autophagy marker detection in formalin fixed paraffin embedded human tissue by immunohistochemistry
Gu et al. Mammalian Atg8 proteins regulate lysosome and autolysosome biogenesis through SNARE s
RU2011141499A (ru) Способ определения пола птиц
CU20230031A7 (es) Método para la detección de anticuerpos antifármaco contra anticuerpos de factor xi y/o factor xia
NO20076662L (no) Deteksjon av et malantigen uavhengig av tilstedevaerelse eller fravaer av et korresponderende terapeutisk antistoff
CN107250799B (zh) 作为生物标志物的游离组蛋白
RU2013142278A (ru) ТЕСТЫ ДЛЯ ДЕТЕКЦИИ АУТОАНТИТЕЛ К АНТИ-TNFα ЛЕКАРСТВЕННЫМ СРЕДСТВАМ
ATE532051T1 (de) Differenzielle reflexionsspektroskopieverfahren zur erkennung von sprengstoffen
MX2021005329A (es) Ensayos de luminiscencia no enzimaticos.
CA2684265A1 (en) Detection of elevated levels of her-2/neu protein from non-isolated circulating cancer cells and treatment
BR112018007842A2 (pt) imunoensaio para a detecção de cininogênio clivado de alto peso molecular, método, anticorpo isolado, kit para detectar um cininogênio de alto peso molecular clivado (hmwk)
CL2011002509A1 (es) Cartucho para la verificacion y el analisis cuantitativo de analito en un liquido de muestra que incorpora una camara de reactivos, una camara de deteccion; procedimiento para analisis cuantitativo de analito; y uso del cartucho.
MX2021010984A (es) Analizador de concentracion en el punto de atencion.
CA2928730A1 (en) Competitive ligand binding assay for detecting neutralizing antibodies
Villarreal et al. Performance of a point of care test for detecting IgM and IgG antibodies against SARS-CoV-2 and seroprevalence in blood donors and health care workers in Panama
Tang et al. Development of quantum dot‐based fluorescence lateral flow immunoassay strip for rapid and quantitative detection of serum interleukin‐6
Kang et al. Development, performance evaluation, and clinical application of a Rapid SARS‐CoV‐2 IgM and IgG Test Kit based on automated fluorescence immunoassay
Jiang et al. Simultaneous determination of gastric cancer biomarkers pepsinogen PGI/PGII using element tagged immunoassay coupled with inductively coupled plasma mass spectrometry detection
Turpin et al. Improvement of immunodetection of the transcription factor C/EBP homologous protein by western blot
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение
Limberg et al. Neurofilament light chain determination from peripheral blood samples
Yang et al. A biotin–streptavidin signal amplification strategy for a highly sensitive chemiluminescent immunoassay for chicken interferon-γ
US11525830B2 (en) Biosensor for detecting influenza A virus using Au—FE3O4 composite
WO2012006540A3 (en) Improving the efficiency of prion conversion in vitro and sensitivity of prion detection
KR102659358B1 (ko) 유리 항원을 이용한 면역 검정법에서의 후크 효과 감지 방법